Boston Therapeutics

Boston Therapeutics is a publicly traded company based in Massachusetts that specializes in developing and commercializing therapeutics for diabetes and related complications. The company is primarily focused on developing a new class of therapeutic compounds called polysaccharides that are designed to reduce the impact of complex carbohydrate intake, which is a major contributor to high blood sugar levels. The compounds in development are based on naturally occurring polysaccharides that have a protective effect on carbohydrates, which may help reduce the risk of developing diabetes or diabetes-related complications, such as cardiovascular disease and neuropathy.

Boston Therapeutics has developed a proprietary technology platform called Galectin Therapeutics, which is a set of carbohydrate-binding agents that have been shown to reduce the absorption of carbohydrates in the digestive tract. These agents have the potential to reduce blood sugar levels in people with diabetes, and may also have applications in preventing the onset of diabetes in pre-diabetic individuals. Additionally, the company is developing a range of other supplements and nutritional products, including dietary fibers that can be used to supplement the diets of people with diabetes and improve glucose control.